Skip to content
ANAVEX
ANAVEXANAVEX
  • HOME
  • ABOUT US
  • OUR TEAM
  • PUBLICATIONS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • OUR TEAM
  • PUBLICATIONS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPIPELINEPress

Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

First Patient Enrolled in Anavex Life Sciences Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease

Anavex Life Sciences Reports Fiscal Third Quarter 2018 Financial Results

Anavex Life Sciences to Announce Fiscal Third Quarter 2018 Financial Results on Thursday, August 9, 2018

Anavex Life Sciences Presents New Data Identifying Treatment Response Biomarkers in Alzheimer’s Disease Patients Treated with Investigational ANAVEX®2-73 at 2018 Alzheimer’s Association International Conference (AAIC)

Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia

Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease

Anavex participates on Brain Health panel at Bio International Conference in Boston

Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results

Anavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018

12345…
67891011121314151617181920212223242526272829303132333435363738394041424344
45
ANAVEX

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2017 All Rights Reserved

Go to Top
Bio CEO Investor Conference
Bio Conference Presentation
Bio CEO Investor Webcast